Browse TRPM4

Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane Multi-pass membrane protein Endoplasmic reticulum Golgi apparatus ; SUBCELLULAR LOCATION: Isoform 2: Cell membrane Endoplasmic reticulum. Golgi apparatus.
Domain PF00520 Ion transport protein
Function

Calcium-activated non selective (CAN) cation channel that mediates membrane depolarization (PubMed:12015988, PubMed:29211723). While it is activated by increase in intracellular Ca(2+), it is impermeable to it (PubMed:12015988). Mediates transport of monovalent cations (Na(+) > K(+) > Cs(+) > Li(+)), leading to depolarize the membrane. It thereby plays a central role in cadiomyocytes, neurons from entorhinal cortex, dorsal root and vomeronasal neurons, endocrine pancreas cells, kidney epithelial cells, cochlea hair cells etc. Participates in T-cell activation by modulating Ca(2+) oscillations after T lymphocyte activation, which is required for NFAT-dependent IL2 production. Involved in myogenic constriction of cerebral arteries. Controls insulin secretion in pancreatic beta-cells. May also be involved in pacemaking or could cause irregular electrical activity under conditions of Ca(2+) overload. Affects T-helper 1 (Th1) and T-helper 2 (Th2) cell motility and cytokine production through differential regulation of calcium signaling and NFATC1 localization. Enhances cell proliferation through up-regulation of the beta-catenin signaling pathway.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001508 action potential
GO:0001649 osteoblast differentiation
GO:0001678 cellular glucose homeostasis
GO:0002027 regulation of heart rate
GO:0002250 adaptive immune response
GO:0002367 cytokine production involved in immune response
GO:0002369 T cell cytokine production
GO:0002407 dendritic cell chemotaxis
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002697 regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002724 regulation of T cell cytokine production
GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002793 positive regulation of peptide secretion
GO:0002819 regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003015 heart process
GO:0003018 vascular process in circulatory system
GO:0003254 regulation of membrane depolarization
GO:0006814 sodium ion transport
GO:0006816 calcium ion transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006936 muscle contraction
GO:0006937 regulation of muscle contraction
GO:0006941 striated muscle contraction
GO:0006942 regulation of striated muscle contraction
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0008015 blood circulation
GO:0008016 regulation of heart contraction
GO:0009306 protein secretion
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009914 hormone transport
GO:0010460 positive regulation of heart rate
GO:0010817 regulation of hormone levels
GO:0015672 monovalent inorganic cation transport
GO:0015833 peptide transport
GO:0016055 Wnt signaling pathway
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0019229 regulation of vasoconstriction
GO:0023061 signal release
GO:0030048 actin filament-based movement
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030278 regulation of ossification
GO:0030279 negative regulation of ossification
GO:0030282 bone mineralization
GO:0030500 regulation of bone mineralization
GO:0030502 negative regulation of bone mineralization
GO:0030595 leukocyte chemotaxis
GO:0031214 biomineral tissue development
GO:0032024 positive regulation of insulin secretion
GO:0032844 regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0032970 regulation of actin filament-based process
GO:0033500 carbohydrate homeostasis
GO:0034284 response to monosaccharide
GO:0035150 regulation of tube size
GO:0035637 multicellular organismal signaling
GO:0035725 sodium ion transmembrane transport
GO:0035773 insulin secretion involved in cellular response to glucose stimulus
GO:0035774 positive regulation of insulin secretion involved in cellular response to glucose stimulus
GO:0036336 dendritic cell migration
GO:0042310 vasoconstriction
GO:0042391 regulation of membrane potential
GO:0042593 glucose homeostasis
GO:0042886 amide transport
GO:0044057 regulation of system process
GO:0045444 fat cell differentiation
GO:0045598 regulation of fat cell differentiation
GO:0045600 positive regulation of fat cell differentiation
GO:0045667 regulation of osteoblast differentiation
GO:0045668 negative regulation of osteoblast differentiation
GO:0045760 positive regulation of action potential
GO:0045823 positive regulation of heart contraction
GO:0045907 positive regulation of vasoconstriction
GO:0045933 positive regulation of muscle contraction
GO:0045989 positive regulation of striated muscle contraction
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046887 positive regulation of hormone secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0050880 regulation of blood vessel size
GO:0050900 leukocyte migration
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0051272 positive regulation of cellular component movement
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051899 membrane depolarization
GO:0055074 calcium ion homeostasis
GO:0055117 regulation of cardiac muscle contraction
GO:0060047 heart contraction
GO:0060048 cardiac muscle contraction
GO:0060070 canonical Wnt signaling pathway
GO:0060326 cell chemotaxis
GO:0060452 positive regulation of cardiac muscle contraction
GO:0060612 adipose tissue development
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061178 regulation of insulin secretion involved in cellular response to glucose stimulus
GO:0061337 cardiac conduction
GO:0061448 connective tissue development
GO:0070167 regulation of biomineral tissue development
GO:0070168 negative regulation of biomineral tissue development
GO:0070252 actin-mediated cell contraction
GO:0070588 calcium ion transmembrane transport
GO:0070838 divalent metal ion transport
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0086001 cardiac muscle cell action potential
GO:0086002 cardiac muscle cell action potential involved in contraction
GO:0086003 cardiac muscle cell contraction
GO:0086004 regulation of cardiac muscle cell contraction
GO:0086014 atrial cardiac muscle cell action potential
GO:0086019 cell-cell signaling involved in cardiac conduction
GO:0086026 atrial cardiac muscle cell to AV node cell signaling
GO:0086065 cell communication involved in cardiac conduction
GO:0086066 atrial cardiac muscle cell to AV node cell communication
GO:0090066 regulation of anatomical structure size
GO:0090087 regulation of peptide transport
GO:0090257 regulation of muscle system process
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0090276 regulation of peptide hormone secretion
GO:0090277 positive regulation of peptide hormone secretion
GO:0098900 regulation of action potential
GO:0098901 regulation of cardiac muscle cell action potential
GO:0098910 regulation of atrial cardiac muscle cell action potential
GO:0198738 cell-cell signaling by wnt
GO:1903115 regulation of actin filament-based movement
GO:1903116 positive regulation of actin filament-based movement
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:1903532 positive regulation of secretion by cell
GO:1903779 regulation of cardiac conduction
GO:1903781 positive regulation of cardiac conduction
GO:1903949 positive regulation of atrial cardiac muscle cell action potential
GO:1904177 regulation of adipose tissue development
GO:1904179 positive regulation of adipose tissue development
GO:1904181 positive regulation of membrane depolarization
GO:1904199 positive regulation of regulation of vascular smooth muscle cell membrane depolarization
GO:1904951 positive regulation of establishment of protein localization
GO:1990736 regulation of vascular smooth muscle cell membrane depolarization
GO:2000021 regulation of ion homeostasis
Molecular Function GO:0005216 ion channel activity
GO:0005227 calcium activated cation channel activity
GO:0005261 cation channel activity
GO:0005262 calcium channel activity
GO:0005272 sodium channel activity
GO:0005516 calmodulin binding
GO:0015077 monovalent inorganic cation transmembrane transporter activity
GO:0015081 sodium ion transmembrane transporter activity
GO:0015085 calcium ion transmembrane transporter activity
GO:0015267 channel activity
GO:0022803 passive transmembrane transporter activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0022839 ion gated channel activity
GO:0046873 metal ion transmembrane transporter activity
GO:0072509 divalent inorganic cation transmembrane transporter activity
Cellular Component GO:0043025 neuronal cell body
GO:0044297 cell body
> KEGG and Reactome Pathway
 
KEGG hsa04911 Insulin secretion
Reactome R-HSA-983712: Ion channel transport
R-HSA-2672351: Stimuli-sensing channels
R-HSA-3295583: TRP channels
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TRPM4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TRPM4 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28614631Prostate CarcinomaInhibit immunityTRPM4 regulates Akt/GSK3-β activity and enhances β-catenin signaling and cell proliferation in prostate cancer cells. This work found that decreasing TRPM4 levels leads to the reduced proliferation of PC3 cells. This effect was associated with a decrease in total β-catenin protein levels and its nuclear localization, and a significant reduction in Tcf/Lef transcriptional activity. TRPM4 silencing increases the Ser33/Ser37/Thr41 β-catenin phosphorylated population and reduces the phosphorylation of GSK-3β at Ser9, suggesting an increase in β-catenin degradation as the underlying mechanism. PC3 cells with reduced levels of TRPM4 showed a decrease in basal and stimulated phosphoactivation of Akt1, which is likely responsible for the decrease in GSK-3β activity in these cells. Our results also suggest that the effect of TRPM4 on Akt1 is probably mediated by an alteration in the calcium/calmodulin-EGFR axis, linking TRPM4 activity with the observed effects in β-catenin-related signaling pathways.
Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TRPM4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TRPM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1520.674
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1130.939
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1960.827
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.320.485
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2810.912
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3640.905
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0130.972
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2690.792
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3440.764
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1490.9
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.6750.701
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1640.166
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TRPM4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.4021.40.081
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414500500.0392
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TRPM4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TRPM4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TRPM4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TRPM4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TRPM4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TRPM4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTRPM4
Nametransient receptor potential cation channel, subfamily M, member 4
Aliases FLJ20041; PFHB1BB; LTrpC4; calcium-activated non-selective cation channel 1; hTRPM4; long transient receptor ......
Chromosomal Location19q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TRPM4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.